Evidence map›Paper›PMID 28431575›Full record

ArticleActa neuropathologica communications2017

Heterogeneous ribonuclear protein A3 (hnRNP A3) is present in dipeptide repeat protein containing inclusions in Frontotemporal Lobar Degeneration and Motor Neurone disease associated with expansions in C9orf72 gene.

Yvonne S Davidson, Louis Flood, Andrew C Robinson, Yoshihiro Nihei, Kohji Mori, Sara Rollinson, Anna Richardson, Bridget C Benson, Matthew Jones, Julie S Snowden and 4 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. RNA-Binding Proteins and the Complex Pathophysiology of ALS.International journal of molecular sciences · 2021
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Yvonne S DavidsonDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK.
Louis FloodDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK.
Andrew C RobinsonDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK.
Yoshihiro NiheiBiomedical Centre (BMC), Biochemistry, Ludwig-Maximilians Universitat Munchen, Munich, Germany.
Kohji MoriBiomedical Centre (BMC), Biochemistry, Ludwig-Maximilians Universitat Munchen, Munich, Germany.
Sara RollinsonDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, A V Hill Building, Manchester, M13 9PT, UK.
Anna RichardsonCerebral Function Unit, Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.
Bridget C BensonDepartment of Molecular Neuroscience, University College London, Institute of Neurology, Queen Square Brain Bank for Neurological Disorders, 1 Wakefield St, London, WC1N 1PJ, UK.
Matthew JonesCerebral Function Unit, Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.
Julie S SnowdenDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK.
Stuart Pickering-BrownDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, A V Hill Building, Manchester, M13 9PT, UK.
Christian HaassBiomedical Centre (BMC), Biochemistry, Ludwig-Maximilians Universitat Munchen, Munich, Germany.
Tammaryn LashleyDepartment of Molecular Neuroscience, University College London, Institute of Neurology, Queen Square Brain Bank for Neurological Disorders, 1 Wakefield St, London, WC1N 1PJ, UK.
David M A MannDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK. david.mann@manchester.ac.uk.
Salford Royal Hospital · GBUniversity of Manchester · GBLudwig-Maximilians-Universität München · DENational Hospital for Neurology and Neurosurgery · GBGerman Center for Neurodegenerative Diseases · DE

Funding

Medical Research Council G0701441
6 · The paper itself

Abstract

Frontotemporal Lobar Degeneration (FTLD) encompasses certain related neurodegenerative disorders which alter behaviour, personality and language. Heterogeneous ribonuclear proteins (hnRNPs) maintain RNA metabolism and changes in their function may underpin the pathogenesis of FTLD. Immunostaining for hnRNP A1, A2/B1 and A3 was performed on sections of temporal cortex with hippocampus from 61 patients with FTLD, stratified by pathological hallmarks into FTLD-tau and FTLD-TDP type A, B and C subtypes, and by genetics into patients with C9orf72 expansions, MAPT or GRN mutations, or those without known mutation. Four patients with Motor Neurone Disease (MND) with C9orf72 expansions and 10 healthy controls were also studied. Semi-quantitative analysis assessed hnRNP staining intensity in dentate gyrus (DG) and CA4 region of hippocampus, and temporal cortex (Tcx) in the different pathological and genetic groups.Immunostaining for hnRNP A1, A2/B1 and A3 revealed no consistent changes in pattern or amount of physiological staining across any of the pathological or genetic groups. No immunostaining of any inclusions resembling TDP-43 immunoreactive neuronal cytoplasmic inclusions or dystrophic neurites, was seen in either Tcx or DG of the hippocampus in any of the FTLD cases investigated for hnRNP A1, A2/B1 and A3. However, immunostaining for hnRNP A3 showed that inclusion bodies, resembling those TDP-43 negative, p62-immunopositive structures containing dipeptide repeat proteins (DPR) were variably observed in hippocampus and cerebellum. The proportion of cases showing hnRNP A3-immunoreactive DPR, and the number of hnRNP A3-positive inclusions within cases, was significantly greater in DG than in cells of CA4 region and cerebellum, but the latter was significantly less in all three regions compared to that detected by p62 immunostaining.

Indexed as

AgedAged, 80 and overC9orf72 ProteinCerebellumDNA-Binding ProteinsDNA Repeat ExpansionFemaleFrontotemporal Lobar DegenerationHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein Group A-BHippocampusHumansInclusion BodiesIntercellular Signaling Peptides and ProteinsMaleMiddle AgedC9orf72 ProteinC9orf72 protein, humanDNA-Binding ProteinsGRN protein, humanHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein Group A-BhnRNP A2HNRNPA3 protein, humanIntercellular Signaling Peptides and ProteinsMAPT protein, humanProgranulinsTARDBP protein, humantau ProteinsC9orf72 geneDipeptide repeat proteinsFrontotemporal Lobar DegenerationHeterogeneous ribonuclear proteinsMotor neuron disease

Identifiers

PMID28431575
PMCPMC5399321
OpenAlexW2606642025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.